NEW HAVEN, CT – November 1, 2005 – HistoRx, Inc., announced today the appointment of Dr. Ronald M. Lindsay, Ph.D., former chief scientific officer and vice president of research and development at diaDexus, Inc., to its board of directors. Dr. Lindsay has more than 20 years experience in neuroscience, cancer, and genomics in the biopharmaceutical industry, including key leadership roles at companies such as Millenium Pharmaceuticals Inc., (NASDAQ: MLNM) and Regeneron Pharmaceuticals Inc., (NASDAQ: REGN). He joins HistoRx at a strategic time, as the Company continues to advance its proprietary quantitative protein diagnostic technology, AQUA™.

“Ron’s scientific expertise in molecular diagnostics and his leadership experience are an asset to HistoRx, as we continue to expand AQUA, our quantitative proteomics and diagnostic platform,” said Dr. Robert A. Curtis, president and chief executive officer of HistoRx. “From his knowledge of the research and development process to his track record in successfully growing a start-up to its full potential, Ron brings the kind of insight and knowledge we need to move through the next phase of our development. We are actively developing additional disease specific reagents to work in conjunction with AQUA, and we are also looking forward to securing additional top-tier collaborations and partnerships in 2007.”

Dr. Lindsay currently heads a biopharmaceutical-consulting firm, Milestone Consulting and is a non-executive director at Sequenom Inc. (NASDAQ: SQNM) and ArQule Inc. (NASDAQ: ARQL). While at diaDexus, Dr. Lindsay led the growth of an R&D effort during a period in which saw diaDexus’ first diagnostic product gain FDA approval. In addition, he managed the initiation of a cancer franchise at diaDexus, creating a large pipeline of potential cancer biomarkers and targets for antibody-based therapies.

“HistoRx is in a very strong phase of growth, with a successfully validated platform in AQUA,” said Dr. Lindsay. “Understanding the spatial profile of protein biomarkers in tissue is an important step in comprehensively tracking disease. The ability of the AQUA system to accurately measure protein expression and localization in diseased tissue sets HistoRx apart. I look forward to assisting HistoRx build its family of tissue and quantitative proteomics products.”

Previous to his leadership roles at diaDexus, Dr. Lindsay served as senior vice president at Millennium Pharmaceuticals Inc. At Millennium Biotherapeutics Inc. he led a gene discovery and preclinical development team, transitioning novel genomic targets through functional validation to a pipeline of product candidates.

Dr. Lindsay was a scientific co-founder of Regeneron Pharmaceuticals Inc. leading research and development in defining therapeutics for neurodegenerative disease, trauma, stroke, ischemia, pain and depression. As vice president, he oversaw the Company’s preclinical efforts in cell biology, animal studies and pharmacology in support of their investigative new drug program.

ABOUT HISTORX, INC.
HistoRx, Inc. is introducing a new generation of advanced quantitative diagnostic products for research and clinical pathology markets based on the company’s proprietary integrated tissue analysis platform, AQUA™, which the company developed from technology pioneered at the Yale University School of Medicine. Initially, HistoRx is providing contract services to the pharmaceutical and biotechnology industries while selectively licensing its technologies to leading academic and not-for-profit research institutions. Simultaneously, the company is advancing development of proprietary fluorescence-based molecular diagnostic tests for use with its AQUA™ platform that will enable biologically based selection of patients who are most likely to benefit from specific therapies. HistoRx is based in New Haven, Conn. For more information, please visit www.historx.com